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Abstract 
Tissue factor (TF)-dependent coagulation contributes to lung inflammation and the 
pathogenesis of acute lung injury (ALI). In this study we explored the roles of targeted 
endothelial anticoagulation in ALI using two strains of transgenic mice expressing either a 
membrane tethered human tissue factor pathway inhibitor (hTFPI) or hirudin fusion protein 
on CD31–positive cells, including vascular endothelial cells (EC). ALI was induced by 
intratracheal injection of LPS, and after 24 hours the expression of TF and protease activated 
receptors (PAR) on EC in lungs were assessed, alongside the extent of inflammation and 
injury. The expression of TF and PARs on the EC in lungs was up-regulated after ALI. In the 
two strains of transgenic mice, expression of either of hTFPI or hirudin by EC was associated 
with significant reduction of inflammation, as assessed by the extent of leukocyte infiltration 
or the levels of proinflammatory cytokines, and promoted survival after LPS-induced ALI. 
The beneficial outcomes were associated with inhibition of the expression of chemokine 
CCL2 in lung tissues. The protection observed in the CD31-TFPI-transgenic strain was 
abolished by injection of an anti-hTFPI antibody, but not by prior engraftment of the 
transgenic strains with WT bone marrow, confirming that the changes observed were a 
specific transgenic expression of anticoagulants by EC. These results demonstrate that the 
inflammation in ALI is TF- and thrombin-dependent, and that expression of anticoagulants by 
EC significantly inhibits the development of ALI via repression of leukocyte infiltration, most 
likely via inhibition of chemokine gradients. These data enhance our understanding of the 
pathology of ALI and suggest a novel therapeutic strategy for treatment. 
Keywords: acute lung injury; lipopolysaccharides; endothelial cells; anticoagulants; human 
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Introduction 
                                                                      
                                                                  
Acute lung injury (ALI) is a clinical syndrome characterized by diffuse interstitial 
pulmonary and noncardiogenic pulmonary edema that results in severe hypoxemia and 
dyspnea [1]. Much of the pathogenesis of ALI is due to EC injury, which leads to 
increased vascular permeability and extensive inflammatory pulmonary infiltrates [1]. 
Because ALI is one of the most frequent causes of morbidity and mortality in critically 
ill patients, there is a need for novel therapeutic targets.  
In ALI or acute respiratory distress syndrome (ARDS), there are mutual 
amplifying interactions between inflammation and coagulation. Abundant evidence 
indicates that coagulopathy is a significant event in systemic inflammation, ALI or 
ARDS. For instance, the infusion of endotoxin or bacteria into the vascular space to 
activate inflammation is quickly followed by intravascular coagulation that is 
activated by enhanced tissue factor (TF) activity [2, 3]. In patients with ARDS, 
evidence of elevated levels of activated coagulation proteins, including thrombin 
(increased 6-fold), soluble TF, activated factor VII (FVIIa), and activated factor X 
(FXa), can be detected in bronchoalveolar lavage fluid (BALF) [4]. The TF-FVIIa 
pathway mediates these coagulation disturbances [5]. Procoagulant TF binds FVIIa,  
and binds and activates FX to FXa, following which downstream coagulation 
proteases can be activated [6].  
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   These effects are accompanied by changes in the levels of physiological regulators 
of coagulators. For instance, antithrombin (AT) levels are reduced in the BALF of 
healthy volunteers after local challenge with either lipoteichoic acid (LTA) (reduced 
by approximately 75%) [7] or lipopolysaccharides (LPS) (reduced by approximately 
83%) [7], as well as in patients with inhalation trauma due to burns (reduced by 
approximately 66%) [8]. Similarly, the TF inhibitory activity of intra-alveolar TFPI 
was reduced through truncation and inactivation (in all but one of 17 patients with 
ARDS, the majority of the TFPI was truncated and likely inactive) [9]. All of these 
observations suggest that coagulation proteases may exacerbate inflammation and 
thus contribute to ALI.  
Coagulation proteases (such as TF-FVIIa complex, FXa and thrombin) can 
activate PARs on the surfaces of EC and monocytes [7], thereby promoting the 
generation of proinflammatory cytokines, for example IL-6, and specific chemokines, 
which can enhance vascular permeability, extravasation of leukocytes and lung injury 
[10]. 
Therapeutic interventions aimed at coagulation blockade have been shown to be 
useful for ALI/ARDS by dampening the inflammatory response. For instance, in a rat 
model of Streptococcus pneumoniae pneumonia, AT treatment promoted 
lung-protective effects (the total histopathology score was improved by approximately 
66%) [11]. In another study, TFPI reduced the lung injury due to Escherichia coli septic 
shock in baboons (the arterial–alveolar oxygen gradient was improved by 
approximately 50%) [12]. In the current studies, the anticoagulants were administered 
5 
 
intravenously, intratracheally or by nebulization, and no assessment of the mechanism 
of action was assessed. We have explored the impact of targeted anticoagulant therapy 
in a mouse model of ALI, using two strains of transgenic mice, CD31-TFPI-Tg and 
CD31-Hir-Tg, that expressed either a membrane-tethered hTFPI or a hirudin fusion 
protein, respectively, on all CD31–positive cells, including vascular ECs, monocytes, 
platelets, polymorphonuclear leukocytes (PMNs) and T cells [13-16]. 
 
Materials and methods 
 
Mice  
The CD31-TFPI-Tg and CD31-Hir-Tg mice have been previously described [13]. The 
transgenic mice express the leech anticoagulant hTFPI and hirudin, which are tethered 
to the cell surface by fusion with fragments of human CD4 and P-selectin. CD31 
[platelet endothelial cell adhesion molecule (PECAM)] promoter control of the 
expression of the transgenes limits the expression to endothelial cells, monocytes, and 
platelets, PMNs and T cells. In addition, the P-selectin sequence directs expression to 
secretory granules. Functional cell surface expression only occurs when the cells are 
activated. Wild type mice (WT, C57BL/6 background, 18-20 g) were purchased from 
the Animal Center of Slaccas (Shanghai, China). All mice were maintained in the 
laboratory animal center of Zhejiang University, which is an accredited animal facility. 
The mice were housed in a room maintained at 23±2 °C with 50%±10% humidity 
and a 12-h light: 12-h dark cycle (lights on from 8:00 a.m. to 8:00 p.m.). In addition, 
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they were allowed free access to water and regular rodent chow (Slaccas, P1101F-25, 
Shanghai, China). All animal experiments complied with the “Guide for the care and 
use of laboratory animals” and were approved by the Animal Care and Use 
Committee at Zhejiang University, China. Genomic DNA from the tails of the 
CD31-TFPI-Tg and CD31-Hir-Tg mice was extracted for genotyping as described [13].  
  
Bone marrow (BM) transplantation 
As described before [17], BM was flushed from the excised ends of long bones from 
WT mice with CD45.1+ BM with normal saline (NS) and resuspended at 2.5×106 cells 
per mL in NS. CD31-TFPI-Tg or CD31-Hir-Tg and WT mice with CD45.2+ BM were 
irradiated with 8 Gy (800 rad) before injection of 1×106 CD45.1+ BM cells in NS into 
a tail vein. The CD45.1 and CD45.2 expression in bone marrow of recipient mice 
before and after BM transplantation was evaluated using flow cytometric analysis 
(data not shown). CD45.2 mice were purchased from the Animal Center of Slaccas 
(Shanghai, China). CD45.1 mice were kindly provided by Professor Lie Wang from 
Zhejiang University School of Medicine. A fluorescein isothiocyanate (FITC)-labeled 
antibody against CD45.1 (eBioscience, 11-0453-81, San Diego, California, USA) and 
an allophycocyanin (APC)-labeled anti-CD45.2 (eBioscience, 17-0454-81, San Diego, 
California, USA) were used. 
 
ALI mouse model 
We anesthetized mice with 1% pentobarbital sodium and then injected 50 µL of a 
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suspension of LPS from Pseudomonas aeruginosa (10 mg/kg) (Sigma-Aldrich, L9143, 
Saint Louis, Missouri, USA) or NS into the trachea with a microsyringe; the mice 
were kept vertical for 1 min to ensure that the LPS or NS was distributed in lungs. 
The mice were sacrificed 24 h later. 
 
Clotting time 
We incubated 100 µL of mouse plasma in a 5 mL plastic tube, added 50 µL of fresh 
BALF to the plasma and incubated the tube for 2 min at 37°C in a water bath. Then, 
we added 100 µL 25 mM CaCl2 to the tube and mixed it well. We measured the time 
to clot formation (observed after gently shaking the tube, the formation of the clot 
observed and the time for the solution to clot was recorded using a stop watch). 
 
Isolated cells from lung 
Isolated lung tissues were cut into small pieces before digestion for 1.5 h with 
collagenase (Sigma-Aldrich, C0130, Saint Louis, Missouri, USA) at 37°C. The 
digested tissues and supernatant were ground and then filtered. The resulting cell 
suspension was centrifuged and resuspended in culture medium [18]. 
 
Flow cytometric analysis 
Cells were incubated simultaneously with Brilliant Violet (BV) 510-, fluorescein 
isothiocyanate (FITC)-, and BV421-labeled antibodies against CD45 (Biolegend, 
103138, San Diego, California, USA), CD11b (Biolegend, 101205, San Diego, 
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California, USA) and Gr-1 (Biolegend, 108445, San Diego, California, USA), 
respectively, for 1 h at 4°C. The stained cells were prepared for flow cytometric 
analysis using a flow cytometer (Beckman Cytoflex, Suzhou, Jiangsu, China). 
Separate aliquots of cells were sequentially incubated with primary rabbit or goat 
antibodies directed against mouse TF (Abcam, ab151748, Cambridgeshire, England, 
UK), PAR-1 (Santa Cruz Biotechnology, sc-8203, Dallas, Texas, USA) or PAR-2 
(Santa Cruz Biotechnology, sc-8205, Dallas, Texas, USA) for 1 h at 4°C, and then, 
they were washed and stained with PE-labeled anti-mouse CD144 (VE-Cadherin) 
(eBioscience, 85-12-1441-80, San Diego, California, USA) and Alexa Fluor 
488-labeled goat anti-Rabbit IgG (H+L) secondary antibody (ThermoFisher Scientific, 
A-11034, Waltham, Massachusetts, USA) or Alexa Fluor 488-labeled donkey 
anti-goat IgG (H+L) secondary antibody (ThermoFisher Scientific, A-11055, Waltham, 
Massachusetts, USA) for 30 min to allow for identification of the CD144+ ECs. The 
stained cells were prepared for flow cytometric analysis using an FC 500 (Cytomics™ 
FC 500, Beckman, Brea, California, USA). 
 
BALF analysis  
The left lungs of the euthanized mice were lavaged 3 times with 0.4 mL PBS. 
Cytospin slides were prepared for Wright-Giemsa staining (BaSO, BA4017, Zhuhai, 
Guangdong, China). An analysis of the numbers of total and differentiated cell counts 
of BALF was performed as previously described [19]. Neutrophils contain intracellular 
granules that stain as a neutral pink and have a nucleus that is divided into 2–5 lobes. 
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Macrophages are larger than neutrophils, stain dark blue and contain a mononucleus 
of a kidney- or horseshoe-shaped or irregular form. 
The total protein levels in the supernatants of BALF were measured using a Pierce 
BCA protein assay kit (Thermo Scientific, 23225, Rockford, Illinois, USA). 
 
RNA isolation and real-time (RT) PCR assay 
We extracted the RNA from lungs with Trizol reagent (Takara Biotechnology, 9109, 
Kusatsu, Shiga, Japan) according to the manufacturer’s instructions. Using gene 
expression assays, we performed RT-PCR on a StepOnePlus Real-Time RCR system 
(Applied Biosystems, Foster City, California, USA). Table 1 shows specific primers 
for RT-PCR that were used to evaluate the gene expression. 
 
ELISA analysis 
The protein expression levels of KC, MIP-2, IL-6, and chemokine (C-C motif) ligand 
2 (CCL2) in the lung homogenates were analyzed using Quantikine ELISAs with 
antibody pairs (R&D Systems, MKC00B, MM200, M6000B, MJE00, Minneapolis, 
MN, USA) according to the manufacturer’s instructions. 
 
Histological assessment 
The right lungs of the euthanized mice were inflated and gravity-fixed (20cm) with 
4% paraformaldehyde followed by paraffin embedding. Axial sections (5 μm) were 
stained with hematoxylin and eosin (H&E). An Olympus BX53 inverted microscope 
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(Olympus, Beijing, China) was used to examine the sections. The histological 
evaluation was performed using methods previously described [20]: For each mouse, 3 
different lobes were examined for the following features: interstitial edema, 
hemorrhage, and neutrophil infiltration. Each feature could receive a score of 0 (no 
injury), 1 (minimal injury), 2 (moderate injury), or 3 (severe injury). These values 
were totaled for a given lobe’s score, and the results for 3 lobes were averaged to 
generate a score for each mouse, giving a minimum score of 0 and a maximum of 9. 
The histological sections were scored by a pathologist blinded to the treatment or 
mouse type. 
 
Mouse lung wet/dry ratio assay 
The lungs of the euthanized and exsanguinated mice were isolated and weighed to 
determine the wet weight before being dried at 60°C for 72 h to obtain the dry weight. 
 
Mouse alveolar-capillary leak assay 
Some mice received 20 mg/kg Evans blue (EB) solution (Sigma-Aldrich, E2129, 
Saint Louis, Missouri, USA) by intravenous injection, 22 h after intratracheal LPS 
and 2 h prior to euthanasia and exsanguination. The lungs were isolated, dipped into 
formamide solution (BIOSHARP, BS335A, Hefei, Anhui, China) and incubated at 
60°C for 24 h. Afterwards, the supernatants were measured for the absorbance of EB 
at 620 nm. 
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Survival rate  
Mice recovered from anesthesia after intratracheal LPS; they were observed daily 
until 168 h to assess survival of each group.  
 
Statistical analysis 
All results were presented as the means ± SEM from each group of three independent 
experiments, which enrolled 5-11 mice per group. An unpaired t test was used to 
compare the two groups. One-way analysis of variance (ANOVA) with the Bonferroni 
correction was applied to determine the interactions among multiple groups. The 
Log-rank (Mantel-Cox) Test was performed for analysis of survival rate. If P < 0.05, 
the differences were considered statistically significant. 
   
Results 
 
LPS induces lung inflammation and coagulation and activates the 
TF-thrombin-PARs pathway in mouse lung ECs 
To determine whether LPS induces lung inflammation and coagulation, WT mice 
were intratracheally instilled with LPS or NS and sacrificed after 24 h. We then 
evaluated the lung inflammatory cell infiltration using flow cytometric analysis and 
BALF cell differential counting, and the coagulation using the BALF clotting time 
assay. The total cell numbers [(4.438 ± 0.7585) ×104 vs (113.9 ± 12.51) ×104, 
WT-CON vs WT -LPS, Mean ± SEM (hereinafter), P<0.001, Fig. 1a] and the 
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neutrophil numbers [(0.03406 ± 0.008477) ×104 vs (96.83 ± 9.47) ×104, P<0.001, Fig. 
1b)] in the BALF were increased by LPS treatment. The results were consistent with 
those of the flow cytometric analysis for the percentage of neutrophils in the white 
blood cells in the suspensions of the lung tissue cells (20.19% ± 2.102% vs 67.96% ± 
2.010%, P<0.001, Fig. 1d-f). The clotting time for BALF (187.8 ± 3.902 vs 71.50 ± 
4.890 s, P<0.001, Fig. 1c) was shortened in the LPS group. 
To examine whether the EC-specific TF-thrombin-PARs pathway was involved in the 
LPS-induced ALI, the expression levels of TF, PAR1 and PAR2 on the ECs from the 
lung tissue were measured using flow cytometric analysis in the ALI model for WT 
mouse. Compared with the NS controls, the expression levels of TF (38.12%± 1.99% 
vs 74.02% ± 1.65%, P<0.001, Fig. 1g-i), PAR1 [(5.16% ± 0.337% vs 13.44% ± 
1.562%, P<0.001, Fig. 1j-l), and PAR2 (6.933% ± 0.4529% vs 13.86% ± 1.657%, 
P<0.01, Fig. 1m-o) in the CD144+ (the indicative molecule of ECs) cells of the WT 
lung tissue were increased in the LPS group. These data demonstrate that LPS 
activates the TF-thrombin-PARs pathway in pulmonary ECs. 
 
Both CD31-TFPI-Tg and CD31-Hir-Tg mice protect LPS-induced ALI 
To assess the different levels of ALI, the WT, CD31-TFPI-Tg and CD31-Hir-Tg mice 
were intratracheally instilled with LPS or NS and sacrificed after 24 h. The total cell 
numbers [(113.9 ± 12.51) ×104 vs (59.8 ± 5.822) ×104 or (63.88 ± 7.542) ×104, 
WT-LPS vs CD31-TFPI-Tg -LPS or CD31-Hir-Tg -LPS (hereinafter), P<0.001, 
respectively, Fig. 2a], the neutrophil numbers (96.83 ± 9.47) ×104 vs (54.15 ± 5.411)  
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×104 or (46.49 ± 9.929) ×104, P<0.001, respectively, Fig. 2b) and the total protein 
(1.253 ± 0.1589 vs 0.5767 ± 0.1053 or 0.7108 ± 0.1352 mg/mL, P<0.001 or P<0.01, 
respectively, Fig. 2l) in the BALF were increased by the LPS treatment. Interestingly, 
compared with WT-LPS group, all of these inflammatory markers were decreased in 
both CD31-TFPI-Tg-LPS and CD31-Hir-Tg-LPS groups. Consistent with the above 
results, the increased gene expression of KC (235.5 ± 45.85- vs 118.0 ± 27.87- or 
52.66 ± 9.389-fold, P<0.01 or P<0.001, respectively, Fig. 2c), MIP-2 (1124 ± 351.8- 
vs 296.3 ± 77.24- or 208.5 ± 41.14-fold, P<0.01 or P<0.001, respectively, Fig. 2e), 
IL-6 (230.3 ± 80.02- vs 67.91 ± 15.68- or 34.38 ± 4.493-fold, P<0.01 or P<0.01, 
respectively, Fig. 2g), TNF-α (176.9 ± 41.7- vs 15.9 ± 2.308- or 20.27 ± 2.147-fold, 
P<0.001 or P<0.001, respectively, Fig. 2i) and IL-1β (64.77 ± 7.855- vs 33.03 ± 
4.336- or 30.13 ± 4.084-fold, P<0.001 or P<0.001, respectively, Fig. 2j), as well as 
the lung edema (ratios of 5.079 ± 0.08718 vs 4.51 ± 0.03138 or 4.686 ± 0.03942, 
P<0.001 or P<0.001, respectively, Fig. 2m), alveolar-capillary leak (28.04 ± 2.845 vs 
13.49 ± 2.193 or 16.61 ± 2.319 µg/g, P<0.001 or P<0.01, respectively, Fig. 2n) and 
focal histological injury in the lung tissue (scores of 7.667 ± 0.4216 vs 5.0 ± 0.3651 or 
4.667 ± 0.3333, P<0.001 or P<0.001, respectively, Fig. 2p-q) that were seen in the 
WT-LPS group, were also mitigated in the CD31-TFPI-Tg-LPS and 
CD31-Hir-Tg-LPS groups. The results for the protein expression levels of KC (431.8 
± 44.08 vs 256.4 ± 23.79 or 187.3 ± 31.95 pg/100 mg, P<0.001, respectively, Fig. 2d), 
MIP-2 (361.3 ± 26.04 vs 234.2 ± 28.68 or 215.9 ± 32.17 pg/100 mg, P<0.01 or 
P<0.001, respectively, Fig. 2f) and IL-6 (76.88 ± 9.951 vs 33.06 ± 5.067 or 30.48 ± 
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2.098 pg/100 mg, P<0.001, respectively, Fig. 2h) were consistent with those for the 
RT-PCR for mRNA. Compared with WT-LPS group, the gene expression levels of the 
anti-inflammatory cytokine IL-10 (42.90 ± 3.482- vs 82.62 ± 12.34- or 88.59 ± 
13.22-fold, P<0.05 or P<0.01, respectively, Fig. 2k) were elevated in the 
CD31-TFPI-Tg-LPS and CD31-Hir-Tg-LPS groups. The survival of the transgenic 
animals after LPS was higher than that of mice in the WT-LPS group (Fig. 2o) 
(P<0.05). These data indicate that targeted expression of hTFPI or Hirudin by CD31+ 
cells can improve ALI in mice. 
 
Anti-hTFPI-neutralizing antibody abolishes the protective effect of CD31 
-TFPI-Tg mice in ALI 
To further assess the protective effect of targeted expression of hTFPI in LPS-induced 
ALI in mice, we administered anti-hTFPI neutralizing antibody through tail vein 
injection. In these experiments, the reduced inflammation and injury seen in 
CD31-TFPI-Tg mice that were administered LPS were again evident, but these effects 
were abolished by the anti-hTFPI. Therefore, there were no observable differences in 
total cell numbers [(99.11 ± 6.309) ×104 vs (111.3 ± 6.425) ×104, WT-LPS vs 
CD31-TFPI-Tg-LPS-anti-TFPI (hereinafter), P>0.05, Fig. 3a), neutrophil numbers 
(93.53 ± 8.318) ×104 vs (105.4 ± 6.203) ×104, P>0.05, Fig. 3b), and total protein 
(0.7802 ± 0.07309 vs 0.6839 ± 0.06103 mg/mL, P>0.05, Fig. 3l) in the BALF, the 
gene expression levels of KC (96.42 ± 14.02- vs 84.97 ± 19.03-fold, P>0.05, Fig. 3c), 
MIP-2 (299.9 ± 40.12- vs 312.1 ± 33.91-fold, P>0.05, Fig. 3e), IL-6 (91.01 ± 24.19- 
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vs 83.2 ± 12.4-fold, P>0.05, Fig. 3g), TNF-α (88.32 ± 18.94- vs 86.3 ± 13.00-fold, 
P>0.05, Fig. 3i), IL-1β (60.62 ± 7.130- vs 58.40 ± 8.271-fold, P>0.05, Fig. 3j) and 
IL-10 (44.72 ± 4.659- vs 46.40 ± 4.877-fold, P>0.05, Fig. 3k) and focal histological 
injury in lung tissue (scores of 7.333 ± 0.3333 vs 7.5 ± 0.4282, P>0.05, Fig. 3m-n) 
between CD31-TFPI-Tg mice that received the anti-hTFPI neutralizing antibody and 
WT mice. The results for the protein expression levels of KC (460.4 ± 41.23 vs 478.3 
± 57.70 pg/100 mg, P>0.05, Fig. 2d), MIP-2 (398.4 ± 25.02 vs 409.7 ± 23.16 pg/100 
mg, P>0.05, Fig. 2f) and IL-6 (95.09 ± 4.087 vs 79.32 ± 6.602 pg/100 mg, P>0.05, 
Fig. 2h) were consistent with those of the RT-PCR for mRNA. These results indicate 
that the protective effect of CD31-TFPI-Tg mice in ALI is completely dependent on 
the membrane-expressed hTFPI. 
 
CD31-TFPI-Tg and CD31-Hir-Tg mice engrafted with WT bone marrow exert 
similar protective effects in LPS-induced ALI 
Because CD31+ cells include ECs, monocytes, platelets, PMNs and T cells, to exclude 
the influence of the targeted expression of hTFPI on hemocytes, CD31-TFPI-Tg-LPS 
and CD31-Hir-Tg mice were engrafted with WT bone marrow for 8 weeks and were 
then subjected to LPS-induced ALI. Not surprisingly, all of the inflammatory markers, 
including the total cell numbers (97.4 ± 8.403) ×104 vs (57.75 ± 6.245) ×104 or (45.9 
± 6.515) ×104, WT/WT-LPS vs WT/CD31-TFPI-Tg -LPS or WT/CD31-Hir-Tg -LPS 
(hereinafter), P<0.001, respectively, Fig. 4a), the neutrophil numbers (93.0 ± 8.104) 
×104 vs (52.29 ± 5.881) ×104 or (42.47 ± 11.25) ×104, P<0.001, respectively, Fig. 4b) 
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and total protein (1.163 ± 0.1521 vs 0.5408 ± 0.05562 or 0.5768 ± 0.1293 mg/mL, 
P<0.001 or P<0.01, respectively, Fig. 4l) in the BALF, as well as the gene expression 
levels of KC (49.0 ± 7.134- vs 23.37 ± 3.612- or 25.03 ± 3.473-fold, P<0.001 or 
P<0.01, respectively, Fig. 4c), MIP-2 (105.0 ± 14.57- vs 55.28 ± 8.62- or 54.72 ± 
10.17-fold, P<0.01, respectively, Fig. 4e), IL-6 (68.58 ± 11.26- vs 27.12 ± 10.37- or 
33.85 ± 6.625-fold, P<0.01 or P<0.05, respectively, Fig. 4g), TNF-α (111.4 ± 23.16- 
vs 22.87 ± 2.433- or 24.66 ± 2.947-fold, P<0.001, respectively, Fig. 4i), IL-1β (56.35 
± 6.058- vs 35.96 ± 6.525- or 32.27 ± 5.388-fold, P<0.05 or P<0.01, respectively, Fig. 
4j), the lung edema (ratios of 5.118 ± 0.04009 vs 4.781 ± 0.04957 or 4.711 ± 0.09122, 
P<0.01 or P<0.001, respectively, Fig. 4m) and the histological scores (scores of 6.333 
± 0.3333 vs 4.667 ± 0.2108 or 4.5 ± 0.2236, P<0.01 or P<0.001, respectively, Fig. 
4n-o), were still attenuated in the transgenic mice that had been engrafted with the 
WT bone marrow. The results of the protein expression levels of KC (760.3 ± 112.2 
vs 249.5 ± 48.63 or 244.8 ± 55.93 pg/100 mg, P<0.001, respectively, Fig. 4d), MIP-2 
(700.9 ± 64.25 vs 293.2 ± 50.80 or 317.2 ± 53.50 pg/100 mg, P<0.001, respectively, 
Fig. 4f) and IL-6 (72.58 ± 12.09 vs 35.50 ± 3.638 or 34.83 ± 5.188 pg/100 mg, 
P<0.001, respectively, Fig. 4h) were consistent with those for the RT-PCR for mRNA. 
Compared with the WT-LPS group, the gene expression level of the 
anti-inflammatory cytokine IL-10 (22.71 ± 2.636- vs 50.77 ± 4.817- or 55.03 ± 
8.369-fold, P<0.001, respectively, Fig. 4k) was elevated in the CD31-TFPI-Tg-LPS 
and CD31-Hir-Tg-LPS groups. These data indicate that only the expression of the 
membrane-tethered hTFPI and hirudin anticoagulants on ECs gave similar protection 
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from ALI as was seen in non-engrafted mice of either strain, which suggested that 
expression by monocytes, platelets, PMNs and T cells contributed little to the 
protective phenotype. 
 
Significant decrease in the expression level of CCL2 in lung tissue of 
CD31-TFPI-Tg and CD31-Hir-Tg mice, either engrafted or non-engrafted   
To further elucidate the mechanism of the protective effect of the two 
membrane-tethered anticoagulants, we evaluated the chemokine levels in the lung 
tissue of mice with ALI and found that the expression of CCL2 was increased in all 
strains of mice after administration of LPS. However, compared with the WT mice, 
the expression level of CCL2 was lower in both the CD31-TFPI-Tg-LPS and 
CD31-Hir-Tg mice. This outcome was true for both the non-engrafted transgenic mice 
[RT-PCR for mRNA (hereinafter): 228.7 ± 78.01- vs 23.73 ± 1.754- or 43.76 ± 
10.37-fold, P<0.001 or P<0.01, respectively; ELISA for protein (hereinafter): 50.48 ± 
2.852 vs 34.10 ± 3.454 or 26.04 ± 4.291 pg/100 mg, P<0.01 or P<0.001; WT-LPS vs 
CD31-TFPI-Tg-LPS or CD31-Hir-Tg-LPS, respectively, Fig. 5a-b] and for those 
engrafted with WT BM (23.85 ± 3.134- vs 12.64 ± 1.709- or 12.7 ± 1.876-fold, 
P<0.01; 68.66 ± 6.677 vs 30.71 ± 4.938 or 17.08 ± 2.553 pg/100 mg, P<0.001, 
WT/WT-LPS vs WT/CD31-TFPI-Tg-LPS or WT/CD31-Hir-Tg-LPS, respectively, 
Fig. 5e-f). However, this reduction in CCL2 was abolished in the CD31-TFPI-Tg 
mice that received the anti-hTFPI neutralizing antibody (52.05 ± 9.876- vs 52.75 ± 
6.513-fold, P>0.05; 53.40 ± 2.760 vs 54.03 ± 6.856 pg/100 mg, WT-LPS vs 
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CD31-TFPI-Tg-LPS-anti-TFPI, P>0.05, Fig. 5c-d). These data indicated that the 
reduced inflammation and injury seen in the two strains of transgenic mice was 
strongly associated with the reduction in the level of the key chemokine CCL2. 
 
Rationale for the investigation of the CD31-TFPI-Tg or CD31-Hir-Tg mice  
TF and downstream coagulation proteases can exert direct influences on the 
inflammatory cascade. PAR1 has a key role in transforming coagulation protease 
activity into inflammatory signals, and thrombin is the main ligand for PAR1. A 
predominant mechanism by which the fusion proteins hTFPI or hirudin inhibit 
inflammation is by inhibiting the development of local chemokine gradients, 
particularly CCL2. In vivo, these gradients are dependent on thrombin signaling 
through EC-expressed PAR1. The fact that both strains showed the same protective 
response implies that the predominant effect of the hTFPI fusion protein is to inhibit 
thrombin generation (Fig. 6). 
 
Discussion 
 
TF and downstream coagulation proteases can exert direct influences on the 
inflammatory cascade. All of these coagulation products exhibit extensive crosstalk 
with inflammatory mediators [21]. Each of these proteins may have independent effects 
on the lung injury that is associated with ARDS, such as generation of cytokines and 
migration and activation of cells. PARs have a key role in transforming coagulation 
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protease activity into inflammatory signals [22]. Our study indicates that the expression 
of TF and PARs was upregulated on the vascular ECs in the lungs of WT mice in 
LPS-induced ALI. 
It is theoretically possible that therapeutic interventions aimed at blocking the 
coagulation process could influence the inflammation during ALI or ARDS. Several 
preclinical trials have shown that APC or AT treatment significantly diminished 
pulmonary inflammation and attenuated histopathologic lung injury [11, 23]. Systemic 
anticoagulation carries a considerable increase in the risk of bleeding, although for the 
lung, local (inhaled) anti-coagulation could potentially be delivered in the context of 
ALI. Intratracheal administration of TFPI improved airway obstruction and prevented 
respiratory failure and death in the rat model of poison gas-induced ALI [24]. 
Additional preclinical and clinical studies have found that inhaled anticoagulation 
improved the survival in smoke inhalation-induced ALI [25]. In this study, we have 
explored several mechanistic elements of the protection afforded by anticoagulation in 
a model of LPS-induced ALI. We have previously described the generation of two 
strains of transgenic mice, CD31-TFPI-Tg and CD31-Hir-Tg, which express a 
membrane-tethered hTFPI or hirudin fusion proteins, respectively, on CD31+ cells, 
which include vascular ECs, monocytes, platelets, PMNs and T cells [13-16]. 
 The design of the fusion proteins is such that they are only expressed at the cell 
surface when the CD31+ cells have been activated by an inflammatory insult. Our 
previous data suggested that both strains were resistant to the profound coagulation 
disorder induced by systemic (i.e., intravenous) LPS [13, 26]. Moreover, we have also 
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demonstrated that a predominant mechanism by which the fusion proteins inhibit 
inflammation is the inhibition of the development of local chemokine gradients, 
particularly CCL2. In vivo, these gradients are dependent on thrombin signaling 
through EC-expressed PAR1 [27]. The inhibition of the formation of these gradients 
prevents the initiation of leukocyte recruitment at sites of inflammation. More, 
recently, using a third strain of mice in which the hTFPI fusion protein expression 
was targeted to α-smooth muscle actin (SMA)-positive cells, we showed that specific 
inhibition of macrophage migration inhibitory factor by these cells prevented 
development of atherosclerosis, again via inhibition of leukocyte recruitment [28]. This 
is the first study of ALI with these two strains of transgenic mice. 
As reported previously, IL-6 is associated with the inflammation in ARDS [10]. In 
our study, both transgenic stains showed attenuated expression of 
inflammatory factors including IL-6, KC, MIP-2, TNF-α and IL-1β and elevated 
expression of anti-inflammatory factor, IL-10. In line with previous reports that 
showed the effects of anticoagulation in ALI or ARDS, in our ALI model, both strains 
of transgenic mice showed obviously reduced levels of lung inflammation, lung 
edema, alveolar-capillary leak and lung injury, and this was associated with a survival 
rate that was remarkably improved compared with that of the WT mice. The fact that 
both strains showed the same protective response implies that the predominant effect 
of the hTFPI fusion protein is to inhibit thrombin generation. 
We administered an anti-hTFPI neutralizing antibody to the CD31-TFPI-Tg mice, 
and this abolished the protective effect, such that responses to LPS were similar to 
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those seen in WT mice. This confirmed that the protection against LPS-induce ALI 
was due to the functional impact of the hTFPI expression. Unfortunately, we were 
unable to obtain an appropriate anti-hirudin neutralizing antibody, so were unable to 
repeat the same maneuver in the second transgenic strain. 
To assess the contribution of fusion protein expression by platelets, monocytes, 
PMNs and T cells, especially considering that TF can be expressed on the surface of 
monocytes [29], we made BM reconstitution chimeras by engrafting WT bone marrow 
into each of the two transgenic strains. These chimeric animals responded to 
intratracheal LPS in the same way as the parental transgenic mice, which suggested 
that only the expression of anticoagulant proteins on the EC effectively blocked 
LPS-induced ALI. 
CCL2 is a small cytokine that is part of the CC chemokine family. CCL2 recruits 
inflammatory cells to the sites of either tissue injury or infection [30, 31]. CCL2 is 
secreted not only by monocytes [32], macrophages [33] and dendritic cells [34] but also 
by ECs [35-37]. This study focused on the TF-thrombin-PAR1 pathway in the ECs. The 
fusion proteins, hTFPI or hirudin, inhibited the expression of CCL2, which was 
dependent on thrombin signaling through EC-expressed PAR1. We speculate that the 
decrease in the level of expression of CCL2 by the ECs was closely related to the 
reduction of inflammatory cell recruitment in lung and further led to the decrease in 
the overall level of inflammation, although the results did not define which cells were 
the main source of CCL2. A previous study demonstrated that PAR1 signaling 
impacted the expression of CCL2, which was conducive to the recruitment of 
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neutrophils towards inflamed lung tissue [38]. It is known that PAR1 is the 
predominant thrombin receptor expressed on ECs [39]. Consistent with this study and 
our previous work, these new results show that the expression of the chemokine 
CCL2 is upregulated during ALI in WT mice but was reduced in both transgenic 
strains. The results from the neutralizing anti-hTFPI and BM chimera experiments 
were consistent with the concept that inhibition of CCL2 expression within the lung, 
which results in reduced neutrophil accumulation, is one potential mechanism by 
which the fusion proteins protect against LPS-induced ALI. Future studies will focus 
on the identification of the effects of CCL2 in ALI with a CCL2-neutralizing antibody 
or knockout mice.  
All these data are consistent with previous work, mentioned above, which 
demonstrated that coagulation proteases, by activating specific receptors (PARs), 
aggravate lung injury. The results further suggest that local delivery of anticoagulants 
might be a potential therapeutic approach in ALI or ARDS. Specifically, several 
polypeptides could be developed for targeted anticoagulation aimed at the 
inflammatory endothelium of the lung in ARDS. 
It is worth noting that previous work from Dr. Ware's research group, using mice 
with a global absence of mouse TF, has shown that global TF deficiency leads to 
alveolar hemorrhage and potentiates murine ALI and oxidative stress in a direct lung 
injury model [40]. Furthermore, using mice with a cell-specific deletion of TF in the 
lung epithelium, the same investigators have also shown that the lung epithelial TF 
may be protective in the ALI induced directly by LPS [41]. However, these combined 
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approaches failed to identify the TF-expressing cell type or types that are most 
critically involved in the lung response to LPS-induced ALI, and the results were 
consistent with the hypothesis that TF on endothelial cells plays a critical role in 
LPS-ALI. Moreover, the use of a gene knockout approach increased baseline 
intra-alveolar hemorrhage, which raised the possibility that the elevated free 
hemoglobin and lipid peroxidation in lungs of these mice affected the lung 
inflammation that resulted after LPS. Our work used the same LPS-induced ALI 
mouse model, but by specifically targeting the membrane-tethered anticoagulants to 
endothelial cells in a manner in which they were only expressed on the cell membrane 
upon cell activation, we avoided direct interference with baseline TF expression by 
any cell type in the lung, thus avoiding any intra-alveolar hemorrhage.  
In conclusion, our data indicate that targeting EC - tissue factor/thrombin 
dependent inflammation obviously inhibits the development of ALI, and one potential 
mechanism involves the suppression of chemokine gradients and hence the reduction 
of leukocyte infiltration. These data remarkably enhance our understanding of the 
pathology and suggest a novel therapeutic target for the treatment of ALI. 
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Legends to figures 
  
Figure 1. Intratracheal LPS induces lung inflammation (a-b, d-f), coagulation 
activation (c) and an increased expression of TF (g-i), PAR1 (j-l) and PAR2 (m-o) on 
CD144+ (the indicative molecule of ECs) cells in lung during ALI. Compared to NS 
group. n = 5-10 for each group. *P<0.05; **P<0.01; ***P<0.001; ns, no significance. 
Data are presented as Mean ± SEM of three separate experiments. CON, control; LPS, 
lipopolysaccharides; ALI, acute lung injury; WBC, white blood cell; Neut, neutrophil; 
BALF, bronchoalveolar lavage fluid; TF, tissue factor; PAR, protease activated 
receptor; ECs, endothelial cells; WT, wild type. 
 
Figure 2. CD31-TFPI-Tg and CD31-Hir-Tg mice protect against LPS-induced ALI. 
Total cell numbers (a), neutrophil numbers (b), and total protein (l) in BALF, lung 
edema (m) and alveolar-capillary leak (n) after intratracheal instillation of LPS for 24 
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h and the percentage of survival (o). With quantitative real-time PCR, the gene 
expression levels of KC (c), MIP-2 (e), IL6 (g), TNF-α (i), IL-1β (j) and IL-10 (k) 
were detected. With quantikine ELISA analysis, the protein expression levels of KC 
(d), MIP-2 (f) and IL-6 (h) were measured. Representative light photomicrographs 
(100×) of H&E staining of lung tissue (p) and histology score (q). Scale bars=200μm. 
Under the heading of “104 Cells/ml”, a value of 1 designates 10 000 cells/ml. n = 6-11 
for each group. *P<0.05; **P<0.01; ***P<0.001; ns, no significance. Data are presented 
as Mean ± SEM of three separate experiments. CON, control; LPS, 
lipopolysaccharides; ALI, acute lung injury; BALF, bronchoalveolar lavage fluid; EB, 
Evans blue; WT, wild type. 
 
Figure 3. The anti-hTFPI neutralizing antibody abolishes the protective effect of the 
hTFPI fusion protein expressed by CD31-TFPI-Tg mice. Total cell numbers (a), 
neutrophil numbers (b), and total protein (l) in BALF after intratracheal instillation of 
LPS for 24 h. With quantitative real-time PCR, the gene expression levels of KC (c), 
MIP-2 (e), IL6 (g), TNF-α (i), IL-1β (j) and IL-10 (k) were detected. With quantikine 
ELISA analysis, the protein expression levels of KC (d), MIP-2 (f) and IL-6 (h) were 
measured. Representative light photomicrographs (100×) of H&E staining of lung 
tissue (m) and histology score (n). Scale bars=200μm. Under the heading of “104 
Cells/ml”, a value of 1 designates 10 000 cells/ml. n = 6-10 for each group. *P<0.05; 
**P<0.01; ***P<0.001; ns, no significance. Data are presented as Mean ± SEM of three 
separate experiments. CON, control; LPS, lipopolysaccharides; ALI, acute lung injury; 
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BALF, bronchoalveolar lavage fluid; WT, wild type. 
 
Figure 4. CD31-TFPI-Tg and CD31-Hir-Tg mice, engrafted with bone marrow from 
WT mice (WT/CD31-TFPI-Tg and WT/CD31-Hir-Tg mice respectively) are still 
protected against LPS-induced ALI. Total cell numbers (a), neutrophil numbers (b), 
and total protein (l) in BALF, and lung edema (m) after intratracheal instillation of 
LPS for 24 h. With quantitative real-time PCR, the gene expression levels of KC (c), 
MIP-2 (e), IL6 (g), TNF-α (i), IL-1β (j) and IL-10 (k) were detected. With quantikine 
ELISA analysis, the protein expression levels of KC (d), MIP-2 (f) and IL-6 (h) were 
measured. Representative light photomicrographs (100×) of H&E staining of lung 
tissue (o) and histology score (n). Scale bars=200μm. Under the heading of “104 
Cells/ml”, a value of 1 designates 10 000 cells/ml. n = 6-10 for each group. *P<0.05; 
**P<0.01; ***P<0.001; ns, no significance. Data are presented as Mean ± SEM of three 
separate experiments. CON, control; LPS, lipopolysaccharides; ALI, acute lung injury; 
BALF, bronchoalveolar lavage fluid; WT, wild type. 
 
Figure 5. The expression level of CCL2 decreases in lung tissues after LPS 
induced-ALI in CD31-TFPI-Tg and CD31-Hir-Tg mice, either those engrafted with 
WT BM or those non-engrafted. Quantitative real-time PCR and ELISA analysis 
respectively detected the expression level of CCL2 in lung tissues in ALI model of 
CD31-TFPI-Tg and CD31-Hir-Tg mice (a-b), CD31-TFPI-Tg mice receiving 
anti-hTFPI neutralizing antibody (c-d), and WT/CD31-TFPI-Tg and 
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WT/CD31-Hir-Tg mice (e-f). n = 6-10 for each group. *P<0.05; **P<0.01; ***P<0.001; 
ns, no significance. Data are presented as Mean ± SEM of three separate experiments. 
CCL2, chemokine (C-C motif) ligand 2; CON, control; LPS, lipopolysaccharides; 
ALI, acute lung injury; WT, wild type. 
 
Figure 6.  Rationale for the investigation of the CD31-TFPI-Tg or CD31-Hir-Tg 
mice. Tissue factor (TF) and downstream coagulation proteases can exert direct 
influences on the inflammatory cascade. Protease activated receptor 1 (PAR1) has a 
cornerstone role in transforming coagulation protease activity into inflammatory 
signals and thrombin is the main ligand to PAR1. A predominant mechanism by which 
the fusion proteins, human tissue factor pathway inhibitor (hTFPI) or hirudin, inhibit 
inflammation is to inhibit the development of local chemokine gradients, particularly 
CCL2, which in vivo is dependent on thrombin signaling through endothelial cell 
(EC)-expressed PAR1. The fact that both strains showed the same protective response 
implies that the predominant effect of the hTFPI fusion protein is to inhibit thrombin 
generation. 
 
